Susquehanna International Group, LLP Kazia Therapeutics LTD Call Options Transaction History

Susquehanna International Group, LLP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 11, 2021	BUY	$9.1 - $14.71 $30,940 - $50,014	3,400 Added 10.06%	37,200 $367,000
Q1 2021 May 17, 2021	BUY	$8.98 - $12.86 $76,330 - $109,310	8,500 Added 33.6%	33,800 $419,000
Q4 2020 Feb 16, 2021	BUY	$5.61 - $13.47 $141,933 - $340,791	25,300 New	25,300 $219,000

369K

24K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $96.1M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.